Dopaminergic medication normalizes aberrant cognitive control circuit signalling in Parkinson's disease.

ABSTRACT: Dopaminergic medication is widely used to alleviate motor symptoms of Parkinson's disease, but these medications also impact cognition with significant variability across patients. It is hypothesized that dopaminergic medication impacts cognition and working memory in Parkinson's disease by modulating frontoparietal-basal ganglia cognitive control circuits, but little is known about the underlying causal signalling mechanisms and their relation to individual differences in response to dopaminergic medication. Here we use a novel state-space computational model with ultra-fast (490 ms resolution) functional MRI to investigate dynamic causal signalling in frontoparietal-basal ganglia circuits associated with working memory in 44 Parkinson's disease patients ON and OFF dopaminergic medication

SUBMITTER: Cai W 

PROVIDER: S-EPMC10200291 | biostudies-literature | 2022 Nov

REPOSITORIES: biostudies-literature